Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.44 |
| ▸ | IKZF3 | Q9UKT9 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23968142 | 0.77 | CRBN (0.45) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL23919011 | 0.77 | CRBN (0.60) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL24294767 | 0.75 | CRBN (0.39) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL20046654 | 0.75 | CRBN (0.43) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL27267196 | 0.74 | CRBN (0.41) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL20128628 | 0.71 | CRBN (0.51) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL17169675 | 0.71 | CRBN (0.62) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL21763627 | 0.70 | CRBN (0.59) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL17173845 | 0.69 | CRBN (0.50) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL22360812 | 0.68 | CRBN (0.58) | CRBNDDB1IKZF3ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | CRBN 231/4885DDB1 650/4885IKZF3 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.